BPC-157, a gastric pentadecapeptide derived from proteolytic enzyme preparations, and TB-500, a synthetic analogue of thymosin beta-4, represent emerging agents with broad biological activity relevant to tissue repair and cytoprotection
BPC-157 Injection vs Oral Peptide: The Core Pharmacokinetic Difference The central question in the BPC-157 injection vs oral peptide debate is bioavailability the fraction of the administered dose that reaches systemic circulation intact and at therapeutically relevant concentrations
(Note: Its not clear what she meant by FDA pharmacies. The type of compounding pharmacy that the company uses is regulated by state boards of pharmacy, not the FDA.) As far as safety was concerned, the provider told me that people with cancer or who are breastfeeding shouldnt take peptides, and that I might have some soreness at the injection site
This protection is primarily attributed to the elevation of intracellular GSH levels
The Science Behind This Healing Peptide Curious about BPC-157